Some Aspects of Prehospital Thrombolytic Therapy in the Perm Region

Aim. To study data on prehospital thrombolytic therapy in ST elevation myocardial infarction (STEMI) in the Perm Krai, its efficacy and safety.Material and methods. The retrospective analysis using the official statistics and medical records of the emergency medical service, primary vascular departm...

Full description

Bibliographic Details
Main Authors: S. A. Naumov, N. S. Karpunina
Format: Article
Language:English
Published: Столичная издательская компания 2018-09-01
Series:Рациональная фармакотерапия в кардиологии
Subjects:
Online Access:https://www.rpcardio.online/jour/article/view/1717
_version_ 1826949664192069632
author S. A. Naumov
N. S. Karpunina
author_facet S. A. Naumov
N. S. Karpunina
author_sort S. A. Naumov
collection DOAJ
description Aim. To study data on prehospital thrombolytic therapy in ST elevation myocardial infarction (STEMI) in the Perm Krai, its efficacy and safety.Material and methods. The retrospective analysis using the official statistics and medical records of the emergency medical service, primary vascular department and regional vascular center for 2014-2017 was performed. Patients with a history of myocardial infarction in the period from 2015 to the 1st quarter of 2017 were included into the study. Medical records of 65 people with STEMI were studied. Patients were divided into two groups: Group I (n=27) – STEMI with thrombolytic therapy with recombinant staphylokinase; Group II (n=38) – STEMI with thrombolytic therapy with tenecteplase. Indirect signs of the efficacy of thrombolytic therapy, the degree of restoration of blood flow in the infarct-related artery according to coronary angiography, and the development of complications were analyzed. Data on general clinical and echocardiographic studies were collected. A telephone survey of patients was conducted to assess the long-term outcomes at the second stage.Results. Increase in the number of prehospital thrombolytic therapy for acute coronary syndrome with ST elevation for 2014-2017 was found according to medical reports. A change in the proportion of the shares of prehospital thrombolytic therapy and percutaneous coronary intervention was also found. Recombinant staphylokinase was comparable to tenecteplase in efficacy and safety in STEMI patients in the first 12 hours. Large bleeding occurred in 1 (3.7%) case with recombinant staphylokinase and in 2 (5.3%) cases with tenecteplase. The number of life-threatening reperfusion arrhythmias was also comparable: 1 patient per each Group. Telephone contact was established with 21 (77.8%) and 30 (78.9%) patients in Groups, respectively. Relapse of angina was found among the interviewed patients in 3 and 5 cases in Groups, and decompensation of heart failure in 2 patients from Group I, 1 patient in each Group underwent coronary bypass surgery.Conclusion. The accumulation and processing of data on the efficacy and safety of thrombolytic therapy with recombinant staphylokinase and tenecteplase is clinically justified.
first_indexed 2024-03-08T14:02:25Z
format Article
id doaj.art-b626771cebf9481bb8a5f140cb602060
institution Directory Open Access Journal
issn 1819-6446
2225-3653
language English
last_indexed 2025-02-17T22:18:05Z
publishDate 2018-09-01
publisher Столичная издательская компания
record_format Article
series Рациональная фармакотерапия в кардиологии
spelling doaj.art-b626771cebf9481bb8a5f140cb6020602024-12-04T11:48:15ZengСтоличная издательская компанияРациональная фармакотерапия в кардиологии1819-64462225-36532018-09-0114449450010.20996/1819-6446-2018-14-4-494-5001499Some Aspects of Prehospital Thrombolytic Therapy in the Perm RegionS. A. Naumov0N. S. Karpunina1Perm Clinical Cardiological Health CentrePerm State Medical University named after E.A. WagnerAim. To study data on prehospital thrombolytic therapy in ST elevation myocardial infarction (STEMI) in the Perm Krai, its efficacy and safety.Material and methods. The retrospective analysis using the official statistics and medical records of the emergency medical service, primary vascular department and regional vascular center for 2014-2017 was performed. Patients with a history of myocardial infarction in the period from 2015 to the 1st quarter of 2017 were included into the study. Medical records of 65 people with STEMI were studied. Patients were divided into two groups: Group I (n=27) – STEMI with thrombolytic therapy with recombinant staphylokinase; Group II (n=38) – STEMI with thrombolytic therapy with tenecteplase. Indirect signs of the efficacy of thrombolytic therapy, the degree of restoration of blood flow in the infarct-related artery according to coronary angiography, and the development of complications were analyzed. Data on general clinical and echocardiographic studies were collected. A telephone survey of patients was conducted to assess the long-term outcomes at the second stage.Results. Increase in the number of prehospital thrombolytic therapy for acute coronary syndrome with ST elevation for 2014-2017 was found according to medical reports. A change in the proportion of the shares of prehospital thrombolytic therapy and percutaneous coronary intervention was also found. Recombinant staphylokinase was comparable to tenecteplase in efficacy and safety in STEMI patients in the first 12 hours. Large bleeding occurred in 1 (3.7%) case with recombinant staphylokinase and in 2 (5.3%) cases with tenecteplase. The number of life-threatening reperfusion arrhythmias was also comparable: 1 patient per each Group. Telephone contact was established with 21 (77.8%) and 30 (78.9%) patients in Groups, respectively. Relapse of angina was found among the interviewed patients in 3 and 5 cases in Groups, and decompensation of heart failure in 2 patients from Group I, 1 patient in each Group underwent coronary bypass surgery.Conclusion. The accumulation and processing of data on the efficacy and safety of thrombolytic therapy with recombinant staphylokinase and tenecteplase is clinically justified.https://www.rpcardio.online/jour/article/view/1717prehospital thrombolysisperm regionrecombinant staphylokinasetenecteplaseefficacy
spellingShingle S. A. Naumov
N. S. Karpunina
Some Aspects of Prehospital Thrombolytic Therapy in the Perm Region
Рациональная фармакотерапия в кардиологии
prehospital thrombolysis
perm region
recombinant staphylokinase
tenecteplase
efficacy
title Some Aspects of Prehospital Thrombolytic Therapy in the Perm Region
title_full Some Aspects of Prehospital Thrombolytic Therapy in the Perm Region
title_fullStr Some Aspects of Prehospital Thrombolytic Therapy in the Perm Region
title_full_unstemmed Some Aspects of Prehospital Thrombolytic Therapy in the Perm Region
title_short Some Aspects of Prehospital Thrombolytic Therapy in the Perm Region
title_sort some aspects of prehospital thrombolytic therapy in the perm region
topic prehospital thrombolysis
perm region
recombinant staphylokinase
tenecteplase
efficacy
url https://www.rpcardio.online/jour/article/view/1717
work_keys_str_mv AT sanaumov someaspectsofprehospitalthrombolytictherapyinthepermregion
AT nskarpunina someaspectsofprehospitalthrombolytictherapyinthepermregion